Canadian Cancer Trials Group Bulletins


2016 EORTC-NCI-AACR Symposium

Two Canadian Cancer Trials Group (CCTG) Investigational New Drug (IND) trials - IND.221 and IND.226 - were presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.

IND.221, A Dose-Ranging Study of IPH2201 (monalizumab) in Patients with Gynecologic Malignancies, was presented by the study co-chair, Dr. Anna Tinker, Medical Oncologist at the British Columbia Cancer Agency, Vancouver, during the Spotlight session.

Data from the dose-ranging part of the phase I/II trial in 18 patients with advanced gynecologic malignancies showed that monalizumab was well tolerated in this patient population, with no dose-limiting toxicities observed. No major differences in terms of safety were observed across the different dose levels.

IND.226, A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients with Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens, aims to confirm the recommended phase II dose (RP2D) of durvalumab +/- tremelimumab.

Initial results, presented by Dr. Desiree Hao, Medical Oncologist at the Tom Baker Cancer Centre in Calgary, show that durvalumab 15 mg/kg q3w and tremelimumab up to 3 mg/kg q6w has, to date, been safely combined with platinum-doublet chemotherapy.

You can find more information about these trials and view the posters presented at the Symposium by using this link ...

Dr. Lesley Seymour, CCTG IND Program Director, presented iRECIST, a guideline for data management and data collection for trials testing immunotherapeutics on behalf of the RECIST Working Group, at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. The manuscript is also in press at The Lancet Oncology.

The iRECIST recommendations were developed by the RECIST Working Group in collaboration with academic groups, pharmaceutical companies, and global regulatory authorities.

For details about Dr. Seymour's presentation, please visit the ENA Symposium website here